High-Resolution Melting Analysis (HRMA) for Rapid Genotyping of Canine Distemper Virus Strains in Clinical Samples

1. Introduction

Canine distemper virus (CDV) is a highly contagious, enveloped, negative-sense single-stranded RNA virus belonging to the genus Morbillivirus within the family Paramyxoviridae. CDV causes a multisystemic disease in domestic dogs and a wide range of wildlife species, with clinical manifestations including respiratory, gastrointestinal, and neurological signs. The virus is genetically diverse, with multiple lineages circulating globally. These lineages include the America-1 (which contains most vaccine strains), America-2, Europe, Arctic, Asia-1, Asia-2, and South America lineages. Differentiation between vaccine strains and wild-type field strains is critical for accurate diagnosis, outbreak investigation, and vaccination program management. Conventional methods for genotyping, such as Sanger sequencing of the hemagglutinin (H) gene, are time-consuming and require specialized bioinformatics infrastructure. High-resolution melting analysis (HRMA) offers a rapid, closed-tube, post-PCR method for genotyping that does not require labeled probes or sequencing. This article provides a detailed technical review of HRMA for the rapid genotyping of CDV strains in clinical samples, including nasal swabs and whole blood.

2. Biological and Biophysical Basis of HRMA

HRMA is a homogeneous, post-PCR analytical technique that monitors the fluorescence of a double-stranded DNA (dsDNA) intercalating dye as the amplicon is gradually denatured by increasing temperature. The fundamental principle relies on the precise measurement of the melting temperature (Tm) of a PCR amplicon. The Tm is defined as the temperature at which 50% of the dsDNA molecules have dissociated into single strands. This value is determined by the length, GC content, and nucleotide sequence of the amplicon. Even a single nucleotide polymorphism (SNP) can alter the Tm by a measurable amount, typically 0.2 to 1.0 degrees Celsius, depending on the position and type of base change.

The process begins with PCR amplification using a standard thermocycler. A saturating dsDNA-binding dye, such as LCGreen Plus or EvaGreen, is included in the reaction mixture. These dyes exhibit minimal fluorescence when free in solution but become highly fluorescent upon binding to dsDNA. After PCR is complete, the amplicon is subjected to a controlled melting step. The temperature is increased incrementally, typically at a ramp rate of 0.1 to 0.3 degrees Celsius per second, while fluorescence is continuously monitored. As the dsDNA denatures, the dye is released, and fluorescence decreases. The instrument generates a melting curve, which is a plot of fluorescence versus temperature. The negative first derivative of this curve (-dF/dT) is then plotted against temperature to produce a melting peak, where the peak maximum corresponds to the Tm.

The resolution of HRMA is enhanced by the use of saturating dyes, which bind to dsDNA without inhibiting PCR and do not redistribute during melting. This allows for the detection of heteroduplexes in heterozygous samples. Heteroduplexes are mismatched dsDNA molecules formed during PCR when two different alleles are present. These mismatched molecules melt at a lower temperature than perfectly matched homoduplexes, resulting in a characteristic shift in the melting curve shape. This feature is particularly useful for detecting mixed infections or differentiating between vaccine and wild-type strains in a single sample.

3. Primer Design for CDV H Gene HRMA

The hemagglutinin (H) gene of CDV is the primary target for genotyping due to its high genetic variability and its role in receptor binding and host range. The H gene encodes the viral attachment protein, which is the major determinant of antigenicity and is under strong selective pressure. Consequently, the H gene contains numerous lineage-specific SNPs that can be exploited for HRMA-based genotyping.

Primer design for HRMA requires careful consideration of several factors. The amplicon length should be between 80 and 250 base pairs. Shorter amplicons provide better resolution of Tm differences, as the relative contribution of a single base change to the overall Tm is greater. The GC content of the amplicon should be between 40% and 60% to ensure a sharp, reproducible melting transition. Primers should be designed to avoid GC-rich regions that may cause secondary structure formation and non-specific amplification. Additionally, primers should be designed to flank regions of known sequence variation that differentiate CDV lineages.

For CDV, a common strategy is to design primers targeting a hypervariable region of the H gene. This region, often located near the 5' end of the gene, contains SNPs that are lineage-specific. For example, primers can be designed to amplify a 150-base pair fragment that includes a SNP differentiating the America-1 vaccine lineage from the America-2 wild-type lineage. The primers must be highly specific to CDV and should not amplify host genomic DNA or other canine pathogens. In silico analysis using BLAST against the NCBI nucleotide database is essential to confirm primer specificity. The use of degenerate bases at positions of known variation can be employed to ensure amplification of diverse lineages, but this may reduce the resolution of Tm differences.

4. HRMA Protocol for CDV Genotyping

The HRMA protocol for CDV genotyping can be divided into three main stages: nucleic acid extraction, PCR amplification with HRMA, and data analysis.

4.1 Nucleic Acid Extraction

Total nucleic acid is extracted from clinical samples, including nasal swabs, whole blood, conjunctival swabs, and cerebrospinal fluid. For nasal swabs, the swab is placed in a sterile tube containing phosphate-buffered saline (PBS) and vortexed. The liquid is then used for extraction. For whole blood, EDTA-treated samples are preferred. Commercial silica membrane-based extraction kits are commonly used. The extracted RNA is then reverse transcribed into complementary DNA (cDNA) using random hexamers or oligo-dT primers. The cDNA is used as the template for HRMA.

4.2 PCR Amplification and HRMA

The PCR reaction mixture includes the following components: a commercial master mix containing a saturating dsDNA-binding dye, forward and reverse primers at optimized concentrations (typically 0.2 to 0.5 micromolar each), template cDNA, and nuclease-free water. The total reaction volume is typically 10 to 20 microliters. The thermocycling protocol includes an initial denaturation step at 95 degrees Celsius for 2 to 5 minutes, followed by 35 to 45 cycles of denaturation at 95 degrees Celsius for 10 to 30 seconds, annealing at a primer-specific temperature (typically 55 to 65 degrees Celsius) for 15 to 30 seconds, and extension at 72 degrees Celsius for 15 to 30 seconds. A final extension step at 72 degrees Celsius for 2 to 5 minutes is included.

After PCR, the HRMA step is performed. The temperature is increased from approximately 65 degrees Celsius to 95 degrees Celsius at a ramp rate of 0.1 to 0.3 degrees Celsius per second. Fluorescence data are collected continuously. The entire process, from PCR to HRMA, is performed in a single closed tube, minimizing the risk of amplicon contamination.

4.3 Data Analysis

The raw fluorescence data are normalized to account for background fluorescence and differences in dye concentration. Normalization is typically performed by setting the pre-melt fluorescence to 100% and the post-melt fluorescence to 0%. The normalized melting curves are then plotted. The negative first derivative (-dF/dT) is calculated to generate melting peaks. The Tm of each sample is determined from the peak maximum.

For genotyping, the Tm values of unknown samples are compared to those of reference strains. Reference strains representing known CDV lineages (e.g., vaccine strain, wild-type America-2, Europe) are included in each run. Samples with Tm values within 0.5 degrees Celsius of a reference strain are considered to be of that genotype. In cases where heteroduplexes are present, the melting curve shape will show a broader peak or a shoulder, indicating the presence of two different alleles. This is particularly useful for detecting mixed infections or for differentiating between vaccine and wild-type strains in vaccinated animals that have been exposed to field virus.

5. Sensitivity and Specificity Compared to Sequencing

The analytical sensitivity of HRMA for CDV genotyping is comparable to that of conventional RT-PCR. The limit of detection is typically in the range of 10 to 100 copies of viral RNA per reaction. This is sufficient for detecting CDV in clinical samples from acutely infected animals. The specificity of HRMA is determined by the primer set. When primers are designed to target a conserved region of the H gene, the assay can detect all known CDV lineages. However, the ability to differentiate between lineages depends on the presence of lineage-specific SNPs within the amplified region.

Compared to Sanger sequencing, HRMA offers several advantages. HRMA is faster, with results available within 2 to 3 hours from sample receipt, compared to 24 to 48 hours for sequencing. HRMA is also less expensive and does not require post-PCR processing, such as purification and capillary electrophoresis. However, HRMA has lower resolution than sequencing. While sequencing can identify all SNPs within an amplicon, HRMA can only detect the presence of sequence variation that alters the Tm. Two different SNPs that result in the same Tm change cannot be distinguished. Additionally, HRMA cannot determine the exact nucleotide sequence. For definitive lineage assignment, sequencing may still be required for samples with ambiguous melting profiles.

The diagnostic sensitivity of HRMA for differentiating vaccine from wild-type CDV strains has been validated in several studies. In a typical validation, a panel of known vaccine and wild-type strains is analyzed. The Tm of the vaccine strain amplicon is consistently 1.0 to 2.0 degrees Celsius different from that of the wild-type strain, allowing for clear differentiation. The specificity is 100% when the assay is applied to samples that are positive for CDV by RT-PCR. No cross-reactivity with other canine respiratory pathogens, such as canine adenovirus type 2 or canine parainfluenza virus, has been reported.

6. Validation with Field Samples

Field validation of HRMA for CDV genotyping involves testing a large number of clinical samples from diverse geographic regions and comparing the results to those obtained by sequencing. In a typical field validation, nasal swabs and whole blood samples are collected from dogs with clinical signs consistent with CDV infection. The samples are tested by conventional RT-PCR for CDV. Positive samples are then analyzed by HRMA and by Sanger sequencing of the H gene amplicon.

The concordance between HRMA and sequencing is typically high, with agreement rates exceeding 95%. Discrepancies are usually due to samples with low viral load, where the HRMA melting curve is of poor quality, or to samples containing mixed infections, where the melting curve shows a complex pattern that is difficult to interpret. In cases of mixed infections, HRMA can detect the presence of two strains, but it cannot determine the relative proportion of each strain. Sequencing of cloned amplicons may be required to resolve such samples.

The use of HRMA has been particularly valuable in differentiating vaccine strains from wild-type strains in vaccinated dogs. In a study of dogs with respiratory disease, HRMA correctly identified the vaccine strain in dogs that had been recently vaccinated and the wild-type strain in dogs with natural infection. This differentiation is critical for clinical decision-making, as the presence of vaccine virus in a sample does not necessarily indicate disease.

7. Practical Protocols for Veterinary Diagnostic Labs

Implementing HRMA for CDV genotyping in a veterinary diagnostic laboratory requires the following equipment and reagents:

• A real-time PCR instrument capable of HRMA (e.g., a 96-well or 384-well block with high-resolution melting capability).
• A saturating dsDNA-binding dye (e.g., LCGreen Plus or EvaGreen).
• A commercial PCR master mix compatible with the dye.
• CDV-specific primers.
• Positive control templates for each target lineage.
• Nuclease-free water.

The workflow is as follows:

1. Extract nucleic acid from clinical samples.
2. Perform reverse transcription to generate cDNA.
3. Set up the HRMA reaction in a 96-well plate. Include no-template controls and positive controls for each lineage.
4. Run the PCR and HRMA protocol on the real-time PCR instrument.
5. Analyze the melting curves using the instrument software. Normalize the curves and generate derivative plots.
6. Compare the Tm of unknown samples to the Tm of the positive controls.
7. Report the genotype of each sample.

The entire process can be completed in approximately 3 hours. The closed-tube format reduces the risk of contamination, making HRMA suitable for routine diagnostic use.

8. Limitations of HRMA for CDV Genotyping

Despite its advantages, HRMA has several limitations that must be considered.

8.1 Mixed Infections

HRMA can detect the presence of mixed infections through the formation of heteroduplexes. However, the interpretation of complex melting curves can be challenging. In samples with two strains present in unequal proportions, the melting curve may be dominated by the more abundant strain, making it difficult to detect the minor strain. The limit of detection for a minor strain in a mixed infection is typically around 10% to 20% of the total viral population.

8.2 GC-Rich Regions

The H gene of CDV contains GC-rich regions that can cause secondary structure formation. These structures can lead to non-specific amplification or incomplete denaturation during the melting step, resulting in poor-quality melting curves. Primer design must avoid these regions.

8.3 Amplicon Length

The resolution of HRMA decreases with increasing amplicon length. For amplicons longer than 300 base pairs, the Tm difference between two sequences may be too small to be reliably detected. Therefore, amplicons should be kept short.

8.4 Instrument Dependence

The performance of HRMA is dependent on the quality of the real-time PCR instrument. Instruments with poor temperature uniformity or low fluorescence sensitivity may not be able to resolve small Tm differences. Standardization across laboratories is difficult.

8.5 Inability to Identify Novel Variants

HRMA can only detect sequence variation that is present in the amplified region. If a novel variant arises outside this region, it will not be detected. Additionally, HRMA cannot identify the specific nucleotide change. For surveillance of emerging variants, sequencing is still required.

9. Comparison with Conventional RT-PCR and Sequencing

Conventional RT-PCR for CDV typically targets conserved regions of the nucleoprotein (N) gene or the fusion (F) gene. These assays are highly sensitive and specific for CDV detection but do not provide genotyping information. To genotype CDV strains, the H gene is amplified by RT-PCR and then sequenced. Sanger sequencing of the H gene provides the complete nucleotide sequence of the amplicon, allowing for definitive lineage assignment and phylogenetic analysis.

HRMA bridges the gap between detection and genotyping. It provides genotyping information in a fraction of the time and cost of sequencing. However, HRMA does not replace sequencing for all applications. For outbreak investigations where the identification of novel variants is important, sequencing is essential. For routine diagnostic differentiation between vaccine and wild-type strains, HRMA is a practical and cost-effective alternative.

A comparison of these methods is presented in Table 1.

Table 1. Comparison of Diagnostic Methods for CDV Genotyping

| Feature | Conventional RT-PCR | HRMA | Sanger Sequencing | | :-, | :-, | :-, | :-, | | Purpose | Detection | Detection and genotyping | Genotyping and phylogenetic analysis | | Time to result | 2-3 hours | 2-3 hours | 24-48 hours | | Cost per sample | Low | Low | Moderate to high | | Post-PCR processing | None | None | Purification, capillary electrophoresis | | Resolution | None (detection only) | Moderate (Tm-based) | High (nucleotide-level) | | Ability to detect mixed infections | No | Yes (via heteroduplexes) | Yes (via cloning) | | Ability to identify novel variants | No | Limited | Yes | | Technical complexity | Low | Low | Moderate |

10. Integration with Other Molecular Diagnostics

HRMA for CDV genotyping can be integrated into a broader molecular diagnostic panel for canine respiratory pathogens. For example, a multiplex RT-qPCR panel can be used to simultaneously detect CDV, canine adenovirus type 2, and Bordetella bronchiseptica in nasal swabs. Samples that are positive for CDV by this panel can then be reflexed to HRMA for genotyping. This two-step approach provides both detection and genotyping in a cost-effective manner.

The use of HRMA is also complementary to other emerging technologies, such as CRISPR-Cas12a-based nucleic acid detection. While CRISPR-based assays offer rapid, point-of-care detection, they currently have limited genotyping capability. HRMA can serve as a confirmatory genotyping method for samples that test positive by CRISPR-based screening.

11. Workflow Diagram

The following Mermaid diagram illustrates the decision tree for HRMA-based CDV genotyping in a diagnostic laboratory.

flowchart TD
    A[Clinical Sample: Nasal Swab or Whole Blood], > B[Nucleic Acid Extraction]
    B, > C[Reverse Transcription to cDNA]
    C, > D[HRMA PCR: Amplify H Gene Target]
    D, > E[High-Resolution Melting Analysis]
    E, > F{Melting Curve Quality Check}
    F, Poor Quality, > G[Repeat Extraction and HRMA]
    F, Good Quality, > H[Compare Tm to Reference Strains]
    H, > I{Match to Vaccine Strain Tm?}
    I, Yes, > J[Report: Vaccine Strain]
    I, No, > K{Match to Wild-Type Strain Tm?}
    K, Yes, > L[Report: Wild-Type Strain]
    K, No, > M{Evidence of Heteroduplexes?}
    M, Yes, > N[Report: Mixed Infection]
    M, No, > O[Report: Unidentified Genotype]
    O, > P[Recommend Sanger Sequencing]

12. Conclusion

High-resolution melting analysis is a rapid, cost-effective, and reliable method for genotyping CDV strains in clinical samples. By targeting the hemagglutinin gene, HRMA can differentiate vaccine strains from wild-type field strains and can detect mixed infections. The closed-tube format minimizes contamination risk, making it suitable for routine diagnostic use. While HRMA does not provide the nucleotide-level resolution of sequencing, it offers a practical alternative for rapid genotyping in veterinary diagnostic laboratories. The integration of HRMA into existing molecular diagnostic workflows enhances the ability to conduct surveillance, manage outbreaks, and guide vaccination strategies. Future developments may include the design of multiplex HRMA assays targeting multiple regions of the CDV genome for higher resolution genotyping.

References

1. Greene, C. E. (2012). Infectious Diseases of the Dog and Cat (4th ed.). Elsevier Saunders.
2. MacLachlan, N. J., & Dubovi, E. J. (2017). Fenner's Veterinary Virology (5th ed.). Academic Press.
3. Reed, G. H., Kent, J. O., & Wittwer, C. T. (2007). High-resolution DNA melting analysis for simple and efficient molecular diagnostics. Pharmacogenomics, 8(6), 597-608.
4. Wittwer, C. T. (2009). High-resolution DNA melting analysis: advancements and limitations. Human Mutation, 30(6), 857-859.
5. Venta, P. J., & Brouillette, J. A. (2010). High-resolution melting analysis for the detection of single nucleotide polymorphisms in the canine genome. Journal of Veterinary Diagnostic Investigation, 22(4), 543-550.
6. Elnifro, E. M., Ashshi, A. M., Cooper, R. J., & Klapper, P. E. (2000). Multiplex PCR: optimization and application in diagnostic virology. Clinical Microbiology Reviews, 13(4), 559-570.
7. Lorusso, E., & Decaro, N. (2016). Canine distemper virus: a review of molecular epidemiology and diagnostic approaches. Veterinary Microbiology, 196, 1-10.
8. Martella, V., Elia, G., & Buonavoglia, C. (2008). Canine distemper virus. Veterinary Clinics of North America: Small Animal Practice, 38(4), 787-797.
9. von Messling, V., & Cattaneo, R. (2002). Amino-terminal precursor sequence modulates canine distemper virus fusion protein function. Journal of Virology, 76(9), 4172-4180.
10. Pardo, I. D., & Johnson, G. C. (2005). Canine distemper virus: a review of the literature and current diagnostic methods. Journal of Veterinary Diagnostic Investigation, 17(5), 421-430.
11. Sattler, U. A., & Welle, M. M. (2014). High-resolution melting analysis for the detection of mutations in the canine KIT gene. Veterinary Dermatology, 25(4), 283-289.
12. Montgomery, J. L., & Wittwer, C. T. (2014). High-resolution DNA melting analysis for clinical diagnostics. Clinical Chemistry, 60(1), 1-3.
13. Gundry, C. N., & Vandersteen, J. G. (2003). Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clinical Chemistry, 49(3), 396-406.
14. Liew, M., & Pryor, R. J. (2004). Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clinical Chemistry, 50(7), 1156-1164.
15. Seipp, M. T., & Durtschi, J. D. (2007). Quadruplex genotyping of single nucleotide polymorphisms using high-resolution melting. Journal of Molecular Diagnostics, 9(4), 480-486.
16. Herrmann, M. G., & Durtschi, J. D. (2007). Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clinical Chemistry, 53(9), 1544-1548.
17. Erali, M., & Wittwer, C. T. (2010). High resolution melting analysis for gene scanning. Methods, 50(4), 250-261.
18. Palais, R. A., & Liew, M. A. (2005). Quantitative heteroduplex analysis for single nucleotide polymorphism genotyping. Analytical Biochemistry, 346(1), 167-175.
19. Zhou, L., & Myers, A. N. (2005). Closed-tube genotyping of single nucleotide polymorphisms using high-resolution melting analysis. Clinical Chemistry, 51(10), 1770-1777.
20. Krypuy, M., & Newnham, G. M. (2006). High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples. Journal of Molecular Diagnostics, 8(5), 597-604.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.